Medicine is often the cradle of A-share long-term bull stock, with four recommended

[pharmaceutical network pharmaceutical stock market] as an important part of the national economy, pharmaceutical manufacturing industry has maintained rapid growth for a long time In recent years, China's pharmaceutical industry has developed rapidly under the encouragement of national industrial policies and the stimulation of the increasing demand scale of domestic pharmaceutical market year by year It is reported that as a consumer + technology industry, medicine is often the cradle of long-term bull stocks in the A-share market Today, I recommend four pharmaceutical stocks for your reference In 2000, Lianyungang Pharmaceutical Co., Ltd changed its name to Hengrui pharmaceutical, which was listed on the Shanghai Stock Exchange, and established a new drug R & D center with international standards in Shanghai, attracting a group of high-level innovative talents to the world Hengrui pharmaceutical also embarked on the road of transformation from generic pharmaceutical enterprises to innovative pharmaceutical enterprises As one of the domestic innovative drugs, Hengrui pharmaceutical has always been the "Baima stock" in the A-share market, whose main product lines include anti-tumor, anesthesia, contrast agents, etc The return on net assets of the company has been maintained at over 23% for many years, and the net profit has been maintained at over 20% growth rate for many years The R & D strength of the company is very strong The data shows that in the first half of 2019, the sales and management expenses of Hengrui medicine increased steadily, while the R & D expenses increased significantly Among them, the R & D cost was 1.484 billion yuan, an increase of 49.13%, and the R & D cost accounted for 14.80% of the revenue The R & D cost invested strongly supports the company's innovation and development strategy Changchun hi tech domestic biopharmaceutical Co., Ltd has a main product line of growth hormone, syncytial virus vaccine, etc The return on net assets of the company has been kept at more than 16% for many years, and the net profit has been kept at a growth rate of more than 30% for many years As a leading biomedical company in China, the company's performance exceeded expectations As a large human growth hormone manufacturer in China, Changchun hi tech is accelerating its growth with its advanced technology, strong product line and leading market share According to the previous research report issued by Southwest Securities, Changchun hi tech's performance growth rate has been increasing rapidly year by year from - 5.3% in 2013, and 12.1%, 20.1%, 26.1% and 36.5% in 2014-2017 It is expected to increase to a compound growth rate of about 41% in 2018-2020 Wuxi apptec medical research and Development Service Co., Ltd is mainly engaged in the comprehensive and integrated platform service for the discovery, R & D and production of small molecular chemicals The return on net assets of the company has been maintained at over 20% for many years, and the net profit has been maintained at over 25% growth rate for many years The company is the world's leading pharmaceutical R & D service platform with broad market space and expected to maintain rapid growth in performance On October 30, 2019, Wuxi apptec disclosed the third quarter financial report of the company In the first three quarters of 2019, the company achieved operating revenue of 9.279 billion yuan, an increase of 34.06% year on year; net profit attributable to the parent company was 1.765 billion yuan, a decrease of 8.46% year on year; net profit deducting from the non parent company was 1.714 billion yuan, an increase of 36.88% year on year Stable performance New drug R & D in China has entered a time node of explosive growth Driven by demand, cro industry is about to enter an explosive growth period In the current domestic cro competition pattern, Wuxi apptec ranks in the forefront with a market share of 16.40% China's leading clinical contract research organization (CRO) of tag pharmaceutical mainly provides phase I to IV clinical trial technical services, data management and other clinical research services for pharmaceutical product research and development The return on net assets of the company has increased to about 17% in recent two years, and the net profit has maintained a growth rate of more than 56% for many years In 2019, tiger pharmaceutical is expected to achieve a net profit of 795-902 million yuan, a year-on-year increase of 68.45% - 91.13% With the rapid growth of non net profit, the clinical cro industry continued to enjoy a high prosperity In 2019, the company expects to achieve a median net profit of about 849 million yuan, a substantial increase of 80% year-on-year; after deducting the median non recurring profit and loss of 300 million yuan, the median net profit of about 549 million yuan, a year-on-year increase of 53.78% Benefiting from the rapid growth of the industry and the company's outstanding competitive advantages, the industry expects that the company's core business sectors, such as digital, Fonda and grand clinic, will maintain rapid growth